lunes, 29 de septiembre de 2014

WHO Pharmaceuticals Newsletter No. 4, 2014


OMS, 29 de septiembre 2014

Tabla de contenidos


Regulatory Matters
Azathioprine ................................................................................... 4
Docetaxel ....................................................................................... 4
Etonogestrel/ethinyl estradiol slow release vaginal ring ................. 4
Lidocaine Viscous ............................................................................ 4
Methadone (Oral) ............................................................................. 5
Ondansetron .................................................................................... 5
Renin-Angiotensin system (RAS) acting agents ................................ 6
Serotonin Antagonists ...................................................................... 6
Strontium ranelate ........................................................................... 7
Testosterone products ...................................................................... 7


Safety of Medicines
Chlorhexidine solution ...................................................................... 9
Ferumoxytol ...................................................................................... 9
Intravenous dantrolene ..................................................................... 9
Ivabradine ....................................................................................... 10
Meningococcal B Vaccine ................................................................. 10
Meso-2, 3-dimercaptosuccinic acid................................................... 10
Ofatumumab..................................................................................... 11
Fentanyl “patches”............................................................................ 11
Vaccines ....................................................................................... …..11
Voriconazole ...................................................................................... 12
Zolpidem ...................................................................................... …..12


Signal
Agomelatine and Hypotension ......................................................... 13
Dronedarone and Polyneuropathy .................................................... 19
Finasteride and Convulsions ............................................................ 23
Roflumilast and Pneumonia ............................................................. 29
Response from Takeda and Forest Laboratories ................................. 34


disponible en